سعر فبيوماجيكتام 80مجم 30 قرص 2026

Febuxostat 80 mg film-coated tablets (Medizen Pharmaceutical Industries > Magic Pharma-Egypt), 3 strips x 10 film-coated tablets per pack.

• Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis) in adults.Population: AdultsEuropean Medicines Agency (EMA)
• Chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom allopurinol is not advisable; not recommended for asymptomatic hyperuricemia.Population: AdultsDailyMed (U.S. National Library of Medicine)

• EU most commonly reported: gout flares, liver function abnormalities, diarrhoea, nausea, headache, dizziness, dyspnoea, rash, pruritus, arthralgia, myalgia, pain in extremity, oedema and fatigue; rare serious hypersensitivity reactions and sudden cardiac death post-marketing.International label, equivalent formulation · European Medicines Agency (EMA)
• US controlled trials (40 mg / 80 mg): liver function abnormalities 6.6% / 4.6%, nausea 1.1% / 1.3%, arthralgia 1.1% / 0.7%, rash 0.5% / 1.6%.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• EU: hypersensitivity to febuxostat or any excipient.International label, equivalent formulation · European Medicines Agency (EMA)
• US: contraindicated in patients being treated with azathioprine or mercaptopurine.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• US boxed warning: gout patients with established cardiovascular disease treated with ULORIC had a higher rate of CV death than with allopurinol; reserve for patients with inadequate response to, intolerance of, or unsuitability for allopurinol.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• EU: in patients with pre-existing major cardiovascular disease more fatal CV events were seen versus allopurinol in CARES (not confirmed in FAST); treat cautiously with regular monitoring. Serious hypersensitivity reactions (SJS, TEN, anaphylaxis, DRESS) mostly in the first month: stop immediately and never restart. Not recommended with mercaptopurine/azathioprine, in organ transplant recipients or where urate formation is greatly increased (xanthine deposition). Liver function tests before and periodically during treatment; caution with thyroid dysfunction (TSH increases); contains lactose.International label, equivalent formulation · European Medicines Agency (EMA)
• US: fatal and nonfatal hepatic failure reported; obtain liver tests before starting and as clinically indicated. Serious skin and hypersensitivity reactions (SJS, DRESS, TEN) reported; discontinue if suspected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Mercaptopurine/azathioprineEU: not recommended (xanthine oxidase inhibition raises their levels, risk of myelotoxicity); if unavoidable reduce their dose to 20% or less of the previous dose with close monitoring.European Medicines Agency (EMA)
• Azathioprine, mercaptopurineUS: concomitant use contraindicated (increased exposure may lead to toxicity).DailyMed (U.S. National Library of Medicine)
• TheophyllineUS: febuxostat altered theophylline metabolism in an interaction study; use with caution when coadministered.DailyMed (U.S. National Library of Medicine)

• EU: very limited pregnancy data without adverse effects; animal studies show no harm; potential human risk unknown; febuxostat should not be used during pregnancy.International label, equivalent formulation · European Medicines Agency (EMA)
• US: limited data are insufficient to inform a drug-associated risk; no adverse developmental effects in rats and rabbits at exposures up to 40 and 51 times the maximum human exposure.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• EU: unknown whether excreted in human milk; excreted in animal milk with impaired pup development; should not be used while breastfeeding.International label, equivalent formulation · European Medicines Agency (EMA)

• Febuxostat: Potent non-purine selective inhibitor of xanthine oxidase, reducing serum uric acid.